Development of conjugate-by-conjugate structured nanoparticles for oral delivery of docetaxel
This study created newly modified structures of HPMC and chitosan, altering their physicochemical properties that could then retard drug release. The nanoparticles were cytotoxic towards MDA-MB-231 breast cancer cells when docetaxel was loaded in the nanoparticles, particularly the nanoparticles produced in the second approach, demonstrating their ability to kill cancerous cells and their potential for further applications in cancer therapy. Additionally, when Caco-2 cells were used as an absorption model in a transport study, the nanoparticles in the second approach showed their capacity to increase drug permeability across the monolayers of Caco-2 cells compared to the free-drug solution. This study also illustrated the enhanced uptake of the nanoparticles by the Caco-2 cells, implying enhanced absorption through the intestine. Therefore, these oral nanoparticles can be considered for delivery systems of agents that are sensitive to the gastrointestinal tract so that they can be transported across the epithelial cells to the bloodstream to deliver the loading cargo at an optimal concentration.
In this study, we show that LOC389641 is involved in PTC, which suggests that it may be a target for TC therapies. PMID: 32940082 [PubMed - in process]
Conclusion: STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma. PMID: 32940081 [PubMed - in process]
Authors: Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC Abstract Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxid...
Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Biomark Med. 2020 Jul;14(11):929-932 Authors: Fuschillo S, Battiloro C, Rocco D, D Gravara L, Motta A, Maniscalco M PMID: 32940076 [PubMed - in process]
Conclusion: Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC. PMID: 32940075 [PubMed - in process]
Conclusion: This study indicated that approximately a third of the CRC patients are diagnosed with EMAST, hereupon EMAST as a prognostic and predictive biomarker should be more studied clinically. PMID: 32940074 [PubMed - in process]
This article aims to review current advances in revealing relationship between tumors and abnormal N-glycosylation and discuss leading-edge applications of N-glycosylation in developing novel tumor biomarkers. PMID: 32940073 [PubMed - in process]
Contributors : Kristoffer G Rigbolt ; Helene ÆgidiusSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo improve the understanding of the complex biological processes underlying the development of non-alcoholic steatohepatitis (NASH), a multi-omics approach combining bulk RNA-sequencing based transcriptomics, quantitative proteomics and single-cell RNA-sequencing was used to characterize tissue biopsies from histologically validated diet-induced obese (DIO) NASH mice compared to chow-fed controls. Bulk RNA-sequencing and proteomics showed a clear distinction between phenotypes and...
PMID: 32938341 [PubMed - in process]
This study clear implicates computational and experimental studies involving Lys104 of KRASG12D and GEF and provides a target for the analysis of future treatments.